Logo of bmcmedicineLink to Publisher's site
PMC full text:
Published online 2024 Jun 10. doi: 10.1186/s12916-024-03462-4

Table 3

Treatment-related AEs

Adverse eventsAny grade
No. (%)
Grades 3–4
No. (%)
Hematologic adverse events
 Neutropenia28 (80)3 (8.6)
 Anemia19 (54.3)0
 Thrombocytopenia16 (45.7)0
Nonhematologic adverse events
 Alopecia25 (71.4)0
 Fatigue6 (17.1)0
 Anorexia5 (14.3)0
 Myalgia5 (14.3)0
 Paresthesia4 (11.4)0
 Nausea3 (8.6)0
 Rash3 (8.6)0
 Constipation2 (5.7)0
 Increased AST2 (5.7)1 (2.9)
 Increased ALT2 (5.7)1 (2.9)
 Increased blood creatinine1 (2.9)0
 Increased bilirubin1 (2.9)0

AST aspartate transaminase, ALT alanine transaminase

-